Liu Jin-E, Cheng Zikang, Zhao Peixu, Wu Yanfei, Zhu Lingjuan, Yu Chao, Zhou Wei, Wang Tao, Cheng Xiaoshu, Dong Quanbin, Bao Huihui
Department of Cardiovascular Medicine, the Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, No. 1 Minde Road, Nanchang, 330006, Jiangxi, China.
Center for Prevention and Treatment of Cardiovascular Diseases, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
Mater Today Bio. 2025 Dec 17;36:102682. doi: 10.1016/j.mtbio.2025.102682. eCollection 2026 Feb.
The incidence and mortality rates of myocardial infarction (MI) worldwide have exhibited a sustained upward trend. Platelet-rich plasma (PRP) is enriched with a diverse repertoire of growth factors that promote cellular proliferation, revascularization and tissue repair, thereby emerging as a promising therapeutic modality for improving MI prognosis. However, the short half-life and inherent tendency of these growth factors to undergo rapid inactivation have hitherto constrained the clinical translation of PRP. Medical hydrogels are regarded as promising platforms for cardiac tissue engineering and localized drug delivery in the context of MI. Herein, we developed a polyethylene glycol-succinimidyl ester/poly-L-lysine (PEG-NHS/PLL) hydrogel engineered for the integration of PRP. The hydrogel strength could be tailored by adjusting the PLL and PEG-NHS ratio to match individualized post-MI treatment needs, while the optimal gelation time (5-10 s) facilitated clinical translation. Electrostatic interactions between the cationic moieties of PLL and PRP-derived bioactive factors contribute to their sustained and controlled release. Moreover,the hydrogel exhibited a faster release rate of PRP under acidic conditions and demonstrated excellent pH-responsive sustained-release properties. The PEG-NHS/PLL hydrogel facilitated the restoration of cardiac function after MI by suppressing fibrotic remodeling, reducing cardiomyocyte apoptosis, scavenges reactive oxygen (ROS) species and promoting neovascularization.
全球范围内，心肌梗死（MI）的发病率和死亡率呈持续上升趋势。富含血小板血浆（PRP）富含多种促进细胞增殖、血管再生和组织修复的生长因子，因此成为改善MI预后的一种有前景的治疗方式。然而，这些生长因子的半衰期短且具有快速失活的内在倾向，迄今为止限制了PRP的临床转化。医用凝胶被认为是心肌组织工程和MI背景下局部药物递送的有前景的平台。在此，我们开发了一种用于整合PRP的聚乙二醇琥珀酰亚胺酯/聚-L-赖氨酸（PEG-NHS/PLL）水凝胶。通过调整PLL和PEG-NHS的比例可以定制水凝胶强度，以满足MI后个体化治疗需求，同时最佳凝胶化时间（5-10秒）便于临床转化。PLL的阳离子部分与PRP衍生的生物活性因子之间的静电相互作用有助于它们的持续和控释。此外，水凝胶在酸性条件下表现出更快的PRP释放速率，并具有优异的pH响应性缓释特性。PEG-NHS/PLL水凝胶通过抑制纤维化重塑、减少心肌细胞凋亡、清除活性氧（ROS）和促进新血管形成，促进了MI后心脏功能的恢复。
